Cologne, Germany, December 08, 2009 / b3c newswire / - The developer of a novel human expression system derived from amniocytes “CEVEC Pharmaceuticals” and the contract manufacturer Inno Biologics Sdn Bhd, Malaysia, announced today the signing of a strategic license agreement. This license enables Inno Biologics to offer the full potential of production of their diagnostic and preclinical grade material in highest quality with authentic human glycosylation patterns using the novel and proprietary CAP™ expression system.
CAP® Technology is the stable producing human cell line from CEVEC. The non-tumor origin cells have highest expression rates of human proteins grow in serum-free suspension culture and post-translational modifications are human-like.
“After launching our new cell line in the U.S. and European market we are delighted to have now our first customers in Asia/Pacific working with our cells. With expression rates and protein quality outperforming any other human system on the market we are proud to have Inno Biologics working with our unique, state of the art cell line,” Wolfgang Kintzel, Managing Director of CEVEC, comments.
“Because post-translational modifications play a significant role for the bioactivity of recombinant proteins it is very important to produce proteins with human-like glycosylation and sialylation”, Rainer Lichtenberger, CEO of CEVEC, states. “We are looking forward to incorporate the technology from CEVEC in order for us to produce a better drug in the future” added Dato’ Mohd Nazlee Kamal, Group Managing Director of Inno Bio Ventures when asked regarding why the partnership was formed.
Prof. Dr. Rolf Werner Corporate Senior Vice President of the Corporate Division Biopharmaceuticals at Boehringer Ingelheim states: “This agreement between our strategic manufacturing partner Inno Biologics and the innovation partner CEVEC extends the technical capability represented in our Production Alliance Network for contract manufacturing of biopharmaceuticals into human cell line technology for manufacturing of highly glycosylated therapeutical proteins.”
About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules with human glycosylation patterns.
About Inno Biologics Sdn Bhd - www.innobiologics.com
Inno Biologics Sdn Bhd is a contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins using mammalian systems. Based in Malaysia, Inno Biologics operates a cGMP manufacturing facility for the production of biopharmaceutical API. It is the flagship biotech company of Inno Bio Ventures Sdn Bhd, a Malaysian Ministry of Finance Incorporated Company with a close affiliation with Ministry of Science, Technology and Innovation. Inno Biologics Sdn Bhd is a member of the Boehringer Ingelheim Production Alliance Network Biologics and the MIT-Centre for Biomedical Innovation (CBI).
About Boehringer Ingelheim
The Boehringer Ingelheim Group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is one of the leading companies for industrial customer manufacturing of biopharmaceuticals by offering the entire production technology chain in development and production at its biopharmaceutical facilities in Biberach (Germany) and in Vienna (Austria). The large-scale manufacturing sites deliver biopharmaceutical products like therapeutic proteins, fusion proteins, protein scaffolds, monoclonal antibodies, antibody fragments and plasmid DNA. The Biberach site is specialized in highly efficient mammalian cell culture systems with yields well above industry standard in animal component free media. The Austria site offers high-expression in bacteria and yeast with exceptionally high productivities using proprietary systems. In the plasmid DNA manufacturing arena Boehringer Ingelheim in Austria has set the standard and supplies early to late-stage clinical trials with gene-therapeutics and DNA vaccines for its international clients. For more information please visit www.boehringer-ingelheim.com.
